NC-762
- Generic Name
- NC-762
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced or Metastatic Solid TumorsBreast CancerOvarian CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04875806
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath